UY35548A - Péptidos terapéuticos para el tratamiento de trastornos metabólicos. - Google Patents
Péptidos terapéuticos para el tratamiento de trastornos metabólicos.Info
- Publication number
- UY35548A UY35548A UY0001035548A UY35548A UY35548A UY 35548 A UY35548 A UY 35548A UY 0001035548 A UY0001035548 A UY 0001035548A UY 35548 A UY35548 A UY 35548A UY 35548 A UY35548 A UY 35548A
- Authority
- UY
- Uruguay
- Prior art keywords
- treatment
- metabolic disorders
- therapeutic peptides
- pyy
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57545—Neuropeptide Y
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Cell Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a análogos novedosos de PYY que tienen un perfil terapéutico mejorado cuando se comparan con el PYY humano nativo. Estos análogos novedosos de PYY son útiles en el tr atamiento de obesidad, diabetes, y otros trastornos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361818624P | 2013-05-02 | 2013-05-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY35548A true UY35548A (es) | 2014-11-28 |
Family
ID=50842285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001035548A UY35548A (es) | 2013-05-02 | 2014-04-30 | Péptidos terapéuticos para el tratamiento de trastornos metabólicos. |
Country Status (20)
Country | Link |
---|---|
US (2) | US20160108098A1 (es) |
EP (1) | EP2992008B1 (es) |
JP (1) | JP2016519130A (es) |
KR (1) | KR20160003848A (es) |
CN (1) | CN105263957A (es) |
AR (1) | AR096162A1 (es) |
AU (1) | AU2014261111B2 (es) |
BR (1) | BR112015027528B1 (es) |
CA (1) | CA2909045C (es) |
CL (1) | CL2015003199A1 (es) |
EA (1) | EA201591839A1 (es) |
ES (1) | ES2732291T3 (es) |
HK (1) | HK1214829A1 (es) |
MX (1) | MX2015015249A (es) |
PE (1) | PE20151808A1 (es) |
RU (1) | RU2015144632A (es) |
SG (1) | SG11201508469YA (es) |
TW (1) | TW201534616A (es) |
UY (1) | UY35548A (es) |
WO (1) | WO2014178018A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2651398T3 (pl) | 2010-12-16 | 2018-05-30 | Novo Nordisk A/S | Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego |
HRP20231060T1 (hr) | 2012-03-22 | 2023-12-22 | Novo Nordisk A/S | Pripravci peptida glp-1 i njihova priprava |
WO2014178018A1 (en) * | 2013-05-02 | 2014-11-06 | Glaxosmithkline Intellectual Property Development Limited | Therapeutic peptides |
EP3068421B1 (en) | 2013-11-15 | 2019-04-17 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
CN105764919B (zh) | 2013-11-15 | 2021-04-27 | 诺和诺德股份有限公司 | 在位置35具有β-高精氨酸置换的hPYY(1-36) |
WO2016124687A1 (en) * | 2015-02-04 | 2016-08-11 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
TWI694082B (zh) | 2015-06-12 | 2020-05-21 | 丹麥商諾佛 儂迪克股份有限公司 | 選擇性pyy化合物及其用途 |
CA3009880A1 (en) * | 2015-12-28 | 2017-07-06 | Idemitsu Kosan Co., Ltd. | Peptide tag and tagged protein including same |
JOP20190095A1 (ar) | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y |
CN110545838A (zh) | 2017-03-08 | 2019-12-06 | 因塔西亚制药公司 | 用于从药物递送装置施用致恶心化合物的设备和方法 |
EP3746111B1 (en) | 2018-02-02 | 2023-07-19 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant |
US10875902B2 (en) | 2018-04-25 | 2020-12-29 | Janssen Pharmaceutica Nv | Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof |
TWI749381B (zh) * | 2018-11-01 | 2021-12-11 | 美商美國禮來大藥廠 | 蛋白質酪胺酸-酪胺酸類似物及其使用方法 |
CR20220206A (es) | 2019-11-11 | 2022-06-16 | Boehringer Ingelheim Int | Agonistas del receptor npy2 |
IL293522A (en) * | 2019-12-04 | 2022-08-01 | Scripps Research Inst | Peptide conjugates and methods of use |
WO2021212023A1 (en) * | 2020-04-17 | 2021-10-21 | Intarcia Therapeutics, Inc. | Long acting peptide tyrosine tyrosine (pyy) analogs and methods of use |
BR112022025623A2 (pt) | 2020-08-07 | 2023-03-07 | Boehringer Ingelheim Int | Agonistas solúveis de receptores de npy2 |
WO2024038067A1 (en) | 2022-08-18 | 2024-02-22 | Boehringer Ingelheim International Gmbh | Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists |
CN115960258B (zh) * | 2022-09-30 | 2024-01-12 | 广西医科大学附属肿瘤医院 | 一类GLP-1/glucagon/Y2受体三重激动剂及其应用 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
DK134189D0 (da) | 1989-03-20 | 1989-03-20 | Nordisk Gentofte | Insulinforbindelser |
EP0512042B1 (en) | 1990-01-24 | 1998-04-08 | BUCKLEY, Douglas I. | Glp-1 analogs useful for diabetes treatment |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5612052A (en) | 1995-04-13 | 1997-03-18 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
US6413539B1 (en) | 1996-10-31 | 2002-07-02 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
US5612051A (en) | 1995-11-17 | 1997-03-18 | Yue; Samuel K. | Method of treating involuntary muscle dysfunction with relaxin hormone |
DE69739172D1 (de) | 1996-08-08 | 2009-01-29 | Amylin Pharmaceuticals Inc | Regulation gastrointestinaler beweglichkeit |
WO1999007404A1 (en) | 1997-08-08 | 1999-02-18 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
US6117949A (en) | 1998-10-01 | 2000-09-12 | Macromed, Inc. | Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
US6004573A (en) | 1997-10-03 | 1999-12-21 | Macromed, Inc. | Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
ATE381939T1 (de) | 1997-11-14 | 2008-01-15 | Amylin Pharmaceuticals Inc | Neuartige exendin agonisten |
ATE383867T1 (de) | 1997-11-14 | 2008-02-15 | Amylin Pharmaceuticals Inc | Neuartige exendin agonisten |
DE69936446T2 (de) | 1998-02-13 | 2008-03-06 | Amylin Pharmaceuticals, Inc., San Diego | Inotropische und diuretische effekte von exendin und glp-1 |
AU3247799A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
KR100867392B1 (ko) | 2000-08-15 | 2008-11-06 | 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 | 마이크로입자 |
PL205971B1 (pl) * | 2001-09-24 | 2010-06-30 | Imp Innovations Ltd | Zastosowanie PYY₃-₃₆ do wytwarzania leku na ograniczanie apetytu, zmniejszenie otyłości lub do zapobiegania otyłości |
EP2335715A3 (en) * | 2004-02-11 | 2013-12-18 | Amylin Pharmaceuticals, LLC | Pancreatic polypeptide family motifs and polypeptides comprising the same |
AU2005289710A1 (en) * | 2004-09-24 | 2006-04-06 | Merck & Co., Inc. | Combination therapy for the treatment of obesity |
NZ555533A (en) * | 2004-12-13 | 2010-03-26 | Amylin Pharmaceuticals Inc | Pancreatic polypeptide family motifs, polypeptides and methods comprising the same |
PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
GB0504857D0 (en) * | 2005-03-09 | 2005-04-13 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
CA2646704A1 (en) * | 2006-03-23 | 2007-10-04 | Amylin Pharmaceuticals, Inc. | Endothelin and endothelin receptor agonists in the treatment of metabolic diseases |
EP2483308A1 (en) | 2009-09-30 | 2012-08-08 | Glaxo Group Limited | Drug fusions and conjugates with extended half life |
WO2011050008A2 (en) | 2009-10-19 | 2011-04-28 | Amylin Pharmaceuticals, Inc. | Combination therapy comprising administration of an amylinomimetic and a pyy peptidomimetic for effecting weight loss and for treating obesity and related metabolic conditions and disorders |
GB201001333D0 (en) * | 2010-01-27 | 2010-03-17 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
JO3131B1 (ar) | 2010-04-27 | 2017-09-20 | Glaxosmithkline Llc | مركبات كيميائية |
EP2600887A4 (en) * | 2010-07-09 | 2014-01-22 | Amylin Pharmaceuticals Llc | MICROCRYSTALLINE AGONISTS OF Y-RECEPTORS |
GB201101459D0 (en) | 2011-01-27 | 2011-03-16 | Imp Innovations Ltd | Novel compounds and thier effects on fedding behaviour |
WO2014178018A1 (en) * | 2013-05-02 | 2014-11-06 | Glaxosmithkline Intellectual Property Development Limited | Therapeutic peptides |
EP3068421B1 (en) * | 2013-11-15 | 2019-04-17 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
-
2014
- 2014-04-30 WO PCT/IB2014/061123 patent/WO2014178018A1/en active Application Filing
- 2014-04-30 AR ARP140101793A patent/AR096162A1/es unknown
- 2014-04-30 BR BR112015027528-1A patent/BR112015027528B1/pt active IP Right Grant
- 2014-04-30 EA EA201591839A patent/EA201591839A1/ru unknown
- 2014-04-30 PE PE2015002329A patent/PE20151808A1/es not_active Application Discontinuation
- 2014-04-30 MX MX2015015249A patent/MX2015015249A/es unknown
- 2014-04-30 RU RU2015144632A patent/RU2015144632A/ru not_active Application Discontinuation
- 2014-04-30 TW TW103115659A patent/TW201534616A/zh unknown
- 2014-04-30 ES ES14727241T patent/ES2732291T3/es active Active
- 2014-04-30 CN CN201480024836.3A patent/CN105263957A/zh active Pending
- 2014-04-30 JP JP2016511159A patent/JP2016519130A/ja active Pending
- 2014-04-30 SG SG11201508469YA patent/SG11201508469YA/en unknown
- 2014-04-30 US US14/888,085 patent/US20160108098A1/en not_active Abandoned
- 2014-04-30 CA CA2909045A patent/CA2909045C/en active Active
- 2014-04-30 AU AU2014261111A patent/AU2014261111B2/en active Active
- 2014-04-30 UY UY0001035548A patent/UY35548A/es not_active Application Discontinuation
- 2014-04-30 KR KR1020157034300A patent/KR20160003848A/ko not_active Application Discontinuation
- 2014-04-30 US US14/265,831 patent/US9441023B2/en active Active
- 2014-04-30 EP EP14727241.3A patent/EP2992008B1/en active Active
-
2015
- 2015-10-30 CL CL2015003199A patent/CL2015003199A1/es unknown
-
2016
- 2016-03-09 HK HK16102709.0A patent/HK1214829A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
MX2015015249A (es) | 2016-02-09 |
AR096162A1 (es) | 2015-12-09 |
EP2992008A1 (en) | 2016-03-09 |
RU2015144632A (ru) | 2017-06-07 |
TW201534616A (zh) | 2015-09-16 |
WO2014178018A1 (en) | 2014-11-06 |
US9441023B2 (en) | 2016-09-13 |
CL2015003199A1 (es) | 2016-05-06 |
BR112015027528B1 (pt) | 2023-02-14 |
EA201591839A1 (ru) | 2016-05-31 |
HK1214829A1 (zh) | 2016-08-05 |
CA2909045C (en) | 2022-12-06 |
US20140329742A1 (en) | 2014-11-06 |
SG11201508469YA (en) | 2015-11-27 |
CA2909045A1 (en) | 2014-11-06 |
ES2732291T3 (es) | 2019-11-21 |
CN105263957A (zh) | 2016-01-20 |
AU2014261111B2 (en) | 2017-03-16 |
AU2014261111A1 (en) | 2015-11-19 |
KR20160003848A (ko) | 2016-01-11 |
US20160108098A1 (en) | 2016-04-21 |
BR112015027528A2 (pt) | 2017-12-05 |
PE20151808A1 (es) | 2015-12-16 |
EP2992008B1 (en) | 2019-04-10 |
JP2016519130A (ja) | 2016-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY35548A (es) | Péptidos terapéuticos para el tratamiento de trastornos metabólicos. | |
CY1121462T1 (el) | Ακυλιωμενα αναλογα γλυκαγονης | |
SV2017005594A (es) | Compuestos co-agonistas de glucagon y glp-1 | |
MX2016004907A (es) | Analogos del glucagon. | |
CO7400885A2 (es) | Análogos de glucagón | |
BR112016022465A2 (pt) | agonistas de receptores de glp-1/glucagon duplo peptídicos derivados de exendina-4 | |
ES2765949T8 (es) | Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer | |
AR098738A1 (es) | Análogos del péptido exendina-4 no acilados | |
UY34859A (es) | Análogos peptídicos de la exendina 4. | |
BR112015020911A2 (pt) | anticorpo, uso de uma combinação e método de tratamento | |
UY36779A (es) | Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón | |
BR112018067731A2 (pt) | coagonistas de glucagon e glp-1 para o tratamento de obesidade | |
CL2016000190A1 (es) | Polipéptidos cíclicos para el tratamiento de la insuficiencia cardiaca. | |
CL2018000597A1 (es) | Métodos para tratar enfermedades inflamatorias | |
ECSP16012582A (es) | Compuestos heterocíclicos y métodos de uso | |
EP3148569A4 (en) | Therapeutic tratment of skin disease with recombinant commensal skin microorganisms | |
ECSP19057403A (es) | Usos terapéuticos de un polvo de insectos | |
ECSP16075416A (es) | Anticuerpos de il-21 | |
BR112018010155A2 (pt) | segmentação do receptor formil-peptídeo 2/receptor lipoxina a4 (fpr2/alx) para tratamento de doença cardíaca | |
CL2016001786A1 (es) | Regulación del metabolismo de ornitina para manipular el contenido de glicoformas ricas en manosa de proteínas recombinantes. | |
UY34575A (es) | Composiciones y métodos para el tratamiento de diabetes y/u obesidad | |
UA117933C2 (uk) | Поліпептид, здатний зв'язувати с5-компонент комплементу людини | |
CR20170376A (es) | Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 con lixisenatida | |
BR112017009358A2 (pt) | imunoterapia específica de peptídeo t terapêutico para uso no tratamento de metástase cerebral de um paciente com hla-2 positivo | |
BR112016009572A2 (pt) | Análogo de relaxina humana, composição farmacêutica do mesmo e aplicação farmacêutica do mesmo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20211206 |